{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T09:51:42Z","timestamp":1784886702340,"version":"3.55.0"},"reference-count":26,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,3,25]],"date-time":"2014-03-25T00:00:00Z","timestamp":1395705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2014,4]]},"abstract":"<jats:sec><jats:label\/><jats:p>GC33 is a humanized<jats:styled-content style=\"fixed-case\">mA<\/jats:styled-content>b against human glypican\u20103 (GPC3). In the first\u2010in\u2010human study carried out in the USA, GC33 was well tolerated and showed preliminary antitumor activity in patients with advanced hepatocellular carcinoma. This study aimed to assess the safety, tolerability, and pharmacokinetic characteristics of GC33 in Japanese patients with advanced hepatocellular carcinoma. The study design was a conventional 3\u00a0+\u00a03 dose\u2010escalation design to determine the maximum tolerated dose of GC33 given i.v. at 5, 10, or 20\u00a0mg\/kg weekly. Immunohistochemistry was carried out on tumor biopsies to evaluate GPC3 expression. Thirteen patients were enrolled across the three dose levels, and no patients observed any dose\u2010limiting toxicity up to the highest planned dose of 20\u00a0mg\/kg. The most common adverse events were decreased lymphocyte count, decreased natural killer cell count, increased C\u2010reactive protein, and pyrexia. Grade 3 adverse events (increased blood pressure, decreased lymphocyte count, and decreased platelet count) were observed in two or more patients. The AUC<jats:sub>inf<\/jats:sub>showed a dose\u2010proportional increase from the 5\u00a0mg\/kg dose group to the 20\u00a0mg\/kg dose group. The trough concentrations of GC33 appeared to reach a steady state after the fourth to the sixth dose. Seven of the 13 patients showed stable disease, the other six showed progressive disease. Furthermore, three patients showed long\u2010term stable disease of more than 5\u00a0months. In conclusion, GC33 given at up to 20\u00a0mg\/kg weekly was well tolerated in Japanese patients with advanced hepatocellular carcinoma.<\/jats:p><\/jats:sec>","DOI":"10.1111\/cas.12368","type":"journal-article","created":{"date-parts":[[2014,2,12]],"date-time":"2014-02-12T17:05:21Z","timestamp":1392224721000},"page":"455-462","source":"Crossref","is-referenced-by-count":70,"title":["Japanese phase I study of<scp>GC<\/scp>33, a humanized antibody against glypican\u20103 for advanced hepatocellular carcinoma"],"prefix":"10.1111","volume":"105","author":[{"given":"Masafumi","family":"Ikeda","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology National Cancer Center Hospital East Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Ohkawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Kanagawa Cancer Center Hospital Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Okusaka","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology National Cancer Center Hospital Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Mitsunaga","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology National Cancer Center Hospital East Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Kanagawa Cancer Center Hospital Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chigusa","family":"Morizane","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology National Cancer Center Hospital Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikue","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Furuse","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Kyorin University School of Medicine Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,3,25]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1665-2681(19)31582-0","article-title":"Advanced hepatocellular carcinoma. Review of targeted molecular drugs","volume":"10","author":"Alves RC","year":"2011","journal-title":"Ann Hepatol"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e3181d46ef2"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758834012458480"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70285-7"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857"},{"key":"e_1_2_7_7_1","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S1016-8478(23)13749-6","article-title":"Blocking endogenous glypican\u20103 expression releases Hep 3B cells from G1 arrest","volume":"15","author":"Farooq M","year":"2003","journal-title":"Mol Cells"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200113712"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1006\/excr.1997.3629"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)00689-9"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2010.02359.x"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.10.024"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2008.11.033"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-1973"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2616"},{"key":"e_1_2_7_16_1","first-page":"343","volume-title":"Primary Malignant Tumors of the Liver","author":"Okuda K","year":"2001"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(01)00130-1"},{"key":"e_1_2_7_18_1","first-page":"277","article-title":"Primary liver cancer in Japan: clinicopathologic features and results of surgical treatments","volume":"211","author":"The Liver Cancer Study Group of Japan","year":"1990","journal-title":"Ann Surg"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.32089"},{"key":"e_1_2_7_20_1","unstructured":"Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 2009(v4.03: June 14 2010) DCTD NCI NIH DHHS. [Cited 11 Nov 2013.] Available from URL:http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf."},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.acthis.2008.11.025"},{"issue":"8","key":"e_1_2_7_23_1","first-page":"4244s","article-title":"Use of a monoclonal anti\u2010estrogen receptor antibody in the immunohistochemical evaluation of human tumors","volume":"46","author":"McCarty KS","year":"1986","journal-title":"Cancer Res"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1014414520282"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1159\/000334454"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-3044"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-185280"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcas.12368","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.12368","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cas.12368","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.12368","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T06:05:49Z","timestamp":1716530749000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cas.12368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,25]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["10.1111\/cas.12368"],"URL":"https:\/\/doi.org\/10.1111\/cas.12368","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,25]]}}}